ConductScience.org, home

Paper39005125

Impact of Tyrosine Kinase Inhibitors (TKIs) on Growth in Children and Adolescents with Chronic Myeloid Leukemia: A Systematic Review.

Katsarou D and 5 others. Curr Pharm Des, 2024. Cited by 6 papers, by iCite.

Cite this record

ConductScience Library. Impact of Tyrosine Kinase Inhibitors (TKIs) on Growth in Children and Adolescents with Chronic Myeloid Leukemia: A Systematic Review. Papers, record 39005125. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39005125

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Impact of Tyrosine Kinase Inhibitors (TKIs) on Growth in Children and Adolescents with Chronic Myeloid Leukemia: A Systematic Review.
PubMed
Journal
Curr Pharm Des
PubMed
Year
2024
PubMed
Publication types
Systematic Review, Journal Article
PubMed
Citations, by iCite
6
iCite
Relative citation ratio, by iCite
1.74, provisional
iCite
Revised in PubMed
2024-10-21
PubMed

Authors6

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Katsarou DDimitrahttps://orcid.org/0009-0007-1770-4898
2Kotanidou EPEleni Phttps://orcid.org/0000-0002-8292-4471
3Tsinopoulou VRVasiliki Renginahttps://orcid.org/0000-0002-2531-2313
4Tragiannidis AAthanasioshttps://orcid.org/0000-0003-4294-2605
5Hatzipantelis EEmmanouilhttps://orcid.org/0000-0002-7535-2970
6Galli-Tsinopoulou AAssiminahttps://orcid.org/0000-0002-8503-3893

Source PubMed

Download CSV of authors

Topics7

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Protein Kinase InhibitorsMajor topic
Leukemia, Myelogenous, Chronic, BCR-ABL PositiveMajor topic
Humans
Child
Adolescent
Antineoplastic Agents
Tyrosine Kinase Inhibitors

Source PubMed

Download CSV of topics

References90

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
133435150Chronic Myeloid Leukemia: A Model Disease of the Past, Present and Future.Cells2021https://conductscience.org/library/papers/33435150PubMed
235920965Management of Chronic Myeloid Leukemia in Children and Young Adults.Curr Hematol Malig Rep2022https://conductscience.org/library/papers/35920965PubMed
336485083Treatment of CML in pregnancy.Hematology Am Soc Hematol Educ Program2022https://conductscience.org/library/papers/36485083PubMed
435321439Management of Chronic Myeloid Leukemia and Pregnancy: A Bibliometric Analysis (2000-2020).Front Oncol2022https://conductscience.org/library/papers/35321439PubMed
530370478Chronic Myeloid Leukemia: Beyond BCR-ABL1.Curr Hematol Malig Rep2018https://conductscience.org/library/papers/30370478PubMed
627220498Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors: An Evolving Paradigm of Molecularly Targeted Therapy.Mol Diagn Ther2016https://conductscience.org/library/papers/27220498PubMed
732806528Philadelphia Chromosome-Positive Leukemia in the Lymphoid Lineage-Similarities and Differences with the Myeloid Lineage and Specific Vulnerabilities.Int J Mol Sci2020https://conductscience.org/library/papers/32806528PubMed
812783368Molecular mechanisms of transformation by the BCR-ABL oncogene.Semin Hematol2003https://conductscience.org/library/papers/12783368PubMed
933718985Chronic Myelogenous Leukemia in Childhood.Curr Oncol Rep2021https://conductscience.org/library/papers/33718985PubMed
1019890786Allogeneic stem cell transplantation for pediatric and adolescent patients with CML: results from the prospective trial CML-paed I.Klin Padiatr2009https://conductscience.org/library/papers/19890786PubMed
1125500000Mechanisms of resistance to BCR-ABL TKIs and the therapeutic strategies: A review.Crit Rev Oncol Hematol2015https://conductscience.org/library/papers/25500000PubMed
1236561525Alterations in cellular metabolisms after TKI therapy for Philadelphia chromosome-positive leukemia in children: A review.Front Oncol2022https://conductscience.org/library/papers/36561525PubMed
1334425075Chronic myeloid leukaemia.Lancet2021https://conductscience.org/library/papers/34425075PubMed
1423121646Trends in chronic myeloid leukemia incidence and survival in the United States from 1975 to 2009.Leuk Lymphoma2013https://conductscience.org/library/papers/23121646PubMed
1532127639European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia.Leukemia2020https://conductscience.org/library/papers/32127639PubMed
1636707619Management of children and adolescents with chronic myeloid leukemia in blast phase: International pediatric CML expert panel recommendations.Leukemia2023https://conductscience.org/library/papers/36707619PubMed
1721234820Excellent outcomes of children with CML treated with imatinib mesylate compared to that in pre-imatinib era.Int J Hematol2011https://conductscience.org/library/papers/21234820PubMed
1829498925Dasatinib in Pediatric Patients With Chronic Myeloid Leukemia in Chronic Phase: Results From a Phase II Trial.J Clin Oncol2018https://conductscience.org/library/papers/29498925PubMed
1922207416Population pharmacokinetic and exposure-response analysis of nilotinib in patients with newly diagnosed Ph+ chronic myeloid leukemia in chronic phase.Eur J Clin Pharmacol2012https://conductscience.org/library/papers/22207416PubMed
2020072833Dasatinib.Recent Results Cancer Res2010https://conductscience.org/library/papers/20072833PubMed

See all 90 referencesDownload CSV of references

Cited by5

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 6 citations.

PMIDTitleJournalYearIn PapersSource
42738405Long-Term Offspring Outcomes Following Parental Exposure to BCR::ABL1 Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: A Retrospective Cohort Study with Follow-Up to 24.6 Years.Cancers (Basel)2026https://conductscience.org/library/papers/42738405PubMed
42115566Dasatinib-Associated Chylothorax: A Scoping Review and Pharmacovigilance Analysis.Ther Innov Regul Sci2026https://conductscience.org/library/papers/42115566PubMed
41901263Design, Synthesis, and Biological Evaluation of N,N-Diphenylaniline-Based Derivatives as Antiproliferative Agents and ABL TK Inhibitors Against CML.Pharmaceuticals (Basel)2026https://conductscience.org/library/papers/41901263PubMed
41675902Redefining pediatric leukemia care - innovations in risk assessment and targeted treatment: a narrative review.Ann Med Surg (Lond)2026https://conductscience.org/library/papers/41675902PubMed
41496461Predictors of Response to Imatinib Therapy and Long-Term Outcomes in Paediatric and Adolescent Patients With Chronic Myeloid Leukaemia.Cancer Rep (Hoboken)2026https://conductscience.org/library/papers/41496461PubMed

Download CSV of cited by

Genes3

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
ABL125PubTator's text mininghttps://conductscience.org/library/genes/25NCBI Gene
GH12688PubTator's text mininghttps://conductscience.org/library/genes/2688NCBI Gene
IGF13479PubTator's text mininghttps://conductscience.org/library/genes/3479NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/39005125

GET https://conductscience.org/api/papers/v1/39005125/references?page=2